This week, Marc and Helena are back together in the studio once more, and to mark the midpoint of season two, GOLD's Assistant Editor, Isabel O'Brien, joins them to check in on our guests' predictions for 2022. Hear from Julie Ross, Kay Wesley and Jennifer Cain Birkmose as the team pours over their predictions to see if clinical trials have been drastically decentralised, whether hybrid events are here to stay and if pharma's pandemic push for collaboration has continued.

If you're interested in learning more about the topic areas discussed in this episode, check out the following content:

Remote trials: replicating reality https://www.emg-gold.com/post/remote-trials-replicating-reality

Interview with Claire Skentelbery https://www.emg-gold.com/post/podcast-claire-skentelbery-director-general-europabio

Interview with Judy Stewart https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases

S02 E10: 2022 predictions – where are we now?